Nurix Therapeutics, Inc. (NRIX): R&D Expense
$316.90M
Year ended 2025-11-30
$340.93M
Trailing 12 months to 2026-05-31
+19.8%
3-year compound annual growth
+36.7%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-11-30 | $316.90M | +43.0% | 2026-01-28, From 2024-12-01 |
| 2024-11-30 | $221.63M | +17.2% | 2026-01-28, From 2023-12-01 |
| 2023-11-30 | $189.15M | +2.5% | 2026-01-28, From 2022-12-01 |
| 2022-11-30 | $184.50M | +58.5% | 2025-01-28, From 2021-12-01 |
| 2021-11-30 | $116.43M | +75.1% | 2023-02-09, From 2020-12-01 |
| 2020-11-30 | $66.49M | +47.7% | 2022-01-28, From 2019-12-01 |
| 2019-11-30 | $45.02M | n/a | 2022-01-28, From 2018-12-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $316.90M | +43.0% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $13.18M | -32.7% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $25.99M | -9.9% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $112.21M | -42.5% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $104.00M | -5.1% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $416.03M | +22.6% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $7.76M | +138.6% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $68.73M | -17.6% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $186.83M | +11.7% |
Compare NRIX, SPRY, LAB, ARCT side by side · Screen every company in Pharmaceutical Preparations ↗